Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial, page-277

I'm one of those 206 holders and thanks to shorters I've been able to average down since 2014. The point being movement up or even down by $1.00 in the last month are neither here nor there for us. The quantum change is not the $1.00 and I'm not selling out for a 1 or 2 bagger. While most have had little opportunity to assist in capital raises and contribute directly to the future of meso, I have bought shares when the opportunity has presented. Down rampers can talk all they like but I've done my research and am comfortable with my risk profile. There is enough publically available information out there to allow an informed decision about the future opportunities and if anyone listens to silviu and co speak with authority and wisdom and backed up, then you've done your research. This is not a short game and anyone who thinks it is hasn't done any research in the development of a new drug for a pharma and deserves to miss out on the jumps.